Eyenuk
Eyenuk is a medtech company developing AI-powered autonomous eye screening, led by its FDA-cleared EyeArt system for diabetic retinopathy detection. The platform serves primary care physicians, endocrinologists, ophthalmologists, health plans, and national health systems across 18+ countries.
- Company typePrivate
- Founded2010
- HeadquartersLos Angeles, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Eyenuk does
Eyenuk is a Woodland Hills, California-based medtech company founded in 2010 that develops AI-powered autonomous eye screening technology, with its core EyeArt AI Eye Screening System being the first FDA-cleared AI for autonomous detection of both more-than-mild and vision-threatening diabetic retinopathy. The platform uses deep learning neural networks and image analysis algorithms to assess retinal fundus image quality, detect lesions, and grade disease severity against internationally recognized clinical scales (ICDR, NHS NDESP), returning screening reports in under 60 seconds without requiring eye dilation or expert human grading. EyeArt is compatible with multiple FDA-cleared fundus cameras from manufacturers including Topcon, Zeiss, Centervue, Remidio, CSO, and Next Sight, and the company also offers EyeScreen, a Human+AI diagnostic service combining AI detection with specialist adjudication for ICD-10 compliant reporting.
The product portfolio spans the cleared EyeArt and EyeScreen services, compatible retinal camera hardware, and a pipeline that includes EyeMark (DR progression tracking), EyeArt extensions for AMD and glaucoma detection, and EyeRead UWF (ultra-widefield lesion analysis). Regulatory positioning is unusually deep: FDA 510(k) clearance (2020, expanded 2023 with multi-camera and Real-Time Image Quality Feedback), EU MDR Class IIb CE marking (first EU MDR certification for autonomous AI DR/AMD/glaucoma in Jan 2023), Health Canada Medical Device License, ISO 13485 MDSAP registration, HIPAA compliance audited by A-Lign, and CMS reimbursement under CPT code 92229. The AI Predictive Biomarkers platform extends the underlying technology toward risk assessment for stroke, cardiovascular disease, and Alzheimer's.
Eyenuk operates a sales-led, enterprise-focused go-to-market targeting primary care physicians, endocrinologists, ophthalmologists/optometrists, nurses, health plans/payers, and national health systems across 18+ countries including the US, UK, Norway, Germany, Italy, India, Canada, South Africa, Armenia, and Vietnam. Named customers include the Los Angeles County Department of Health Services (800K+ patients), Norway South-Eastern Regional Health Authority, UK NHS, Discovery Health, Armenian EyeCare Project, Diabetes Center Mergentheim, and the University Eye Clinic of Genoa. Revenue derives from subscription/per-screen licensing of the EyeArt system and per-report fees for the EyeScreen service. The company has raised over $43 million in total funding, including a $26 million Series A in October 2022 led by AXA IM Alts, and in January 2025 appointed Mads Dall as Chairman and Gaurav Agarwal as CEO.
Eyenuk firmographics
Firmographics- Name
- Eyenuk
- Legal name
- Eyenuk, Inc.
- Website
- https://eyenuk.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Eyenuk is a medtech company developing AI-powered autonomous eye screening, led by its FDA-cleared EyeArt system for diabetic retinopathy detection. The platform serves primary care physicians, endocrinologists, ophthalmologists, health plans, and national health systems across 18+ countries.
- Ownership category
- akta.pro rank
Eyenuk industry classification
Industry- Product category
- AI Medical Imaging Software
- NAICS
- Ophthalmic Goods Manufacturing (339115)
- SIC
- Ophthalmic Goods (3851)
- akta.pro primary industry
- Ocular Imaging & Diagnostic Testing Centers (HLAKAKAN)
- akta.pro secondary industries
- Vision & Ophthalmic Diagnostic Centers (Optometry/OCT/Retinal Imaging) (HLAFAKAI), Visual Field & Functional Vision Testing (Perimetry, ERG/VEP, Contrast Sensitivity) (HLAHAJAC)
Keywords
Where Eyenuk is headquartered
LocationHeadquarters
- HQ city
- Los Angeles
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Eyenuk business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Marketing or Sales, Operations
Revenue model
- EyeArt AI Screening System: Revenue from licensing and deploying the EyeArt AI Eye Screening System to healthcare providers including hospitals, clinics, and health systems. The system is sold as a cloud-based software service with per-screen or subscription pricing.
- EyeScreen Human+AI Diagnostic Service: Diagnostic service revenue combining AI screening with human expert grading, providing ICD-10 compliant reports and reimbursable under existing CPT codes.
- Regulatory Compliance Services: Supporting healthcare providers with compliance, HEDIS measure improvement, and CMS Five-Star Quality Ratings through diabetic retinopathy screening programs.
Go-to-market motion2 records
Distribution channels5 records
Marketing channels7 records
Eyenuk product offering
Product offeringCore offering
Eyenuk develops and commercializes the EyeArt AI Eye Screening System, an FDA-cleared, cloud-based software that autonomously analyzes retinal fundus images to detect diabetic retinopathy (and under EU MDR, age-related macular degeneration and glaucoma) without requiring eye dilation or expert human grading. The company also operates the EyeScreen Human+AI Diagnostic Service, which combines the AI with specialist human grading and produces ICD-10 compliant reports.
Product overview
Eyenuk offers a portfolio of AI-powered eye screening products centered on the EyeArt system, which provides autonomous AI detection of diabetic retinopathy and other eye diseases. The core offering includes the EyeArt AI Eye Screening System (FDA-cleared, CE-marked, Health Canada licensed) for primary care and diabetes clinic deployment, complemented by the EyeScreen Human+AI Diagnostic Service that combines AI detection with human expert grading. The company also supplies compatible retinal cameras and maintains a pipeline of products including EyeMark for retinopathy progression tracking and EyeArt extensions for AMD and glaucoma detection. All products leverage deep learning-based computer vision to analyze retinal fundus images, with results returned in under 60 seconds.
Differentiator
Problem solved
Functional benefit
Brands
- EyeArt: AI Eye Screening System for autonomous detection of diabetic retinopathy, age-related macular degeneration, and glaucoma
- EyeScreen
- EyeMark
- EyeRead
Products and services
- EyeArt AI Eye Screening System Cloud-based AI software that autonomously analyzes retinal fundus images to detect diabetic retinopathy (and AMD/glaucoma under EU MDR), returning screening reports in under 60 seconds without eye dilation or expert human grading. Sold to primary care clinics, endocrinology/diabetes centers, ophthalmology practices, health systems, and health plans.
- EyeScreen Human+AI Diagnostic Service Diagnostic service that pairs the EyeArt AI with independent human expert graders (and expert adjudication on disagreement) to identify referable diabetic retinopathy, producing ICD-10 compliant reports for healthcare providers.
Quantifiable outcome
- 96% sensitivity, 88% specificity for detecting more-than-mild DR; 97% sensitivity, 90% specificity for vision-threatening DR in pivotal clinical trial
- +5 more outcomes
Companies that use Eyenuk
Customer profileNamed customers11 records
Segments6 records
Ideal customer profiles4 records
Eyenuk technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature5 records
Eyenuk partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core, flagship, minor and major.
- South-Eastern Norway Regional Health AuthoritycoreFirst national health system deployment of EyeArt autonomous AI eye screening technology for diabetic retinopathy screening across Norway. Eyenuk's technology chosen as part of Norway's National Health System for nationwide DR screening.
- Vision Loss Rehabilitation CanadaflagshipBringing AI-driven diabetic eye screening to rural and Indigenous communities in Northern and Eastern Ontario, Canada, improving access to vision-saving screening in remote areas.
- Population Health AllianceminorEyenuk joined the Population Health Alliance to promote autonomous AI technology for improving diabetes complications management at point-of-care and community settings.
- Discovery Health (South Africa)flagshipDiscovery Health launched EyeArt AI system as a diabetic retinopathy screening benefit for members, making vision-saving screening accessible in South Africa through the Discovery health platform.
- HealthCare Dynamics International (HCDI)majorHCDI, a minority woman-owned healthcare quality improvement company, adopted EyeArt AI technology to help health plans close HEDIS gaps and improve quality measures.
- Fred Hollows FoundationflagshipFred Hollows Foundation supported diabetic eye testing program in Vietnam using Eyenuk's AI technology, extending eye screening to underserved populations.
- Devlyn Optical / Grupo DevlynmajorMultinational optical retailer piloting AI and telemedicine technology using EyeArt for diabetic retinopathy screening at retail optical locations across Latin America.
- World Diabetes FoundationflagshipWorld Diabetes Foundation supported the Armenian EyeCare Project's nationwide DR screening program using EyeArt technology, with approximately $1.5M+ in funding to bring screening to 87 clinics across Armenia.
- Armenian EyeCare ProjectflagshipNonprofit implementing nationwide AI eye screening program in Armenia using EyeArt technology, screening over 10,000 patients with support from World Diabetes Foundation and Ministry of Health of Armenia.
- Retinal Camera Manufacturers (Topcon, Zeiss, Centervue, Remidio, CSO, Next Sight)coreIntegration partnerships with multiple retinal camera manufacturers enabling EyeArt AI analysis to work with various fundus camera systems, providing flexibility for healthcare providers.
Scale indicators5 records
Recent moves7 records
Expansion highlights6 records
Eyenuk competitors and assessment
Company assessmentDirect peers
- AEYE Health: AEYE Health is an AI medical device company developing autonomous DR screening algorithms that compete directly with EyeArt for FDA-cleared, primary-care-deployable diabetic retinopathy detection.
- Digital Diagnostics: Digital Diagnostics (formerly IDx) developed IDx-DR, the first FDA-cleared autonomous AI diagnostic system for diabetic retinopathy, making it the most direct head-to-head competitor to Eyenuk's EyeArt in US primary care and health system channels.
- iHealthScreen: iHealthScreen provides AI-based automated screening for diabetic retinopathy and age-related macular degeneration using retinal image analysis, directly competing with EyeArt in the autonomous AI DR screening category.
- RetinAI Medical: RetinAI Medical (Ikerian) develops AI platforms for ophthalmic image analysis and disease management, including DR and AMD, with similar deep-learning retinal analysis capabilities to Eyenuk's EyeArt.
Emerging players
- MediWhale: MediWhale is an emerging AI health company applying deep learning to retinal fundus images to predict systemic disease risk (cardiovascular, kidney), overlapping with Eyenuk's stated AI Predictive Biomarkers roadmap.
- Thirona: Thirona develops AI-based medical image analysis software including retinal image analysis tools, with comparable computer-vision approach to EyeArt though focused across multiple imaging modalities.
- Aidoc: Aidoc is a clinical AI company deploying deep learning image analysis in healthcare workflows; while focused on radiology rather than ophthalmology, it represents an adjacent peer in regulated clinical-AI deployment and enterprise hospital sales.
Broad incumbents
- Topcon Healthcare: Topcon is a major ophthalmic device manufacturer producing fundus cameras and screening solutions that Eyenuk integrates with; it is both a partner and a potential competitor as it expands AI capabilities into its hardware.
- Carl Zeiss Meditec: Carl Zeiss Meditec is a leading ophthalmic devices and diagnostics company whose fundus cameras integrate with EyeArt; it is a strategic integration partner and a broader incumbent capable of embedding competing AI into its installed base.
- Google Health: Google Health has published and deployed AI models for diabetic retinopathy screening (e.g., in India with Aravind Eye Hospital); its research and product efforts represent a large-scale potential competitor to Eyenuk's autonomous AI DR screening.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Eyenuk social profiles
Digital presenceEyenuk compliance and trust
Trust signalCompliance6 records
Eyenuk financial estimates
Financial estimateRevenue estimate
Valuation estimate
Eyenuk leadership team
Management profileNumber of profiles
Profiles4 records
Eyenuk funding detail
Funding detailFunding overview
Funding rounds13 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Eyenuk M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Eyenuk
What does Eyenuk do?
Eyenuk develops and commercializes the EyeArt AI Eye Screening System, an FDA-cleared, cloud-based software that autonomously analyzes retinal fundus images to detect diabetic retinopathy (and under EU MDR, age-related macular degeneration and glaucoma) without requiring eye dilation or expert human grading. The company also operates the EyeScreen Human+AI Diagnostic Service, which combines the AI with specialist human grading and produces ICD-10 compliant reports.
Is Eyenuk a public or private company?
Eyenuk is a private company. It is classified as venture growth investor backed and is currently operating.
When was Eyenuk founded?
Eyenuk was founded in 2010. It employs 11 to 50 people.
Where is Eyenuk based?
Eyenuk is headquartered in Los Angeles, United States, in the North America region.
How does Eyenuk make money?
Three revenue lines are on record. EyeArt AI Screening System is the primary driver. The others are eyeScreen Human+AI Diagnostic Service and regulatory Compliance Services.
Who are Eyenuk's main competitors?
Direct peers on record are AEYE Health, Digital Diagnostics, iHealthScreen and RetinAI Medical. Emerging players are MediWhale, Thirona and Aidoc. Broad incumbents are Topcon Healthcare, Carl Zeiss Meditec and Google Health.
Does Eyenuk have an API?
No public API is recorded for Eyenuk.
What industry is Eyenuk in?
Eyenuk's product category is AI Medical Imaging Software. Its primary akta.pro industry code is HLAKAKAN, Ocular Imaging & Diagnostic Testing Centers, with a secondary code of HLAFAKAI, Vision & Ophthalmic Diagnostic Centers (Optometry/OCT/Retinal Imaging). Its NAICS code is 339115 and its SIC code is 3851.